Results 81 to 90 of about 9,195 (133)

The Pivotal Role of GR-CAR Pathway in Fetal Programming of Hepatic Cytochrome P450 3A Alteration in Adulthood. [PDF]

Adv Sci (Weinh)
Sun X, Liu J, Xiang E, Li X, Yan X, Wang Y, Li F, Kou H, Wang H, Guo Y.   +9 more
europepmc   +1 more source

Outcomes following exposure to drug interactions with ibrutinib in patients with chronic lymphocytic leukaemia. [PDF]

Br J Haematol
Hoang T, Cheung MC, Juurlink DN, Chan KKW, Lau C, Liu N, Abdel-Qadir H, Prica A, Hay AE, Vijenthira A, Mozessohn L.   +10 more
europepmc   +1 more source

Physiologically Based Pharmacokinetic Modeling in Patients With Hepatic Impairment: Are Changes in Bosutinib Exposure Profiles Driven by Altered Absorption or Distribution? [PDF]

CPT Pharmacometrics Syst Pharmacol
Muto C, Jones HM, Yamazaki S.
europepmc   +1 more source

Estrogen associations with human pregnancy related increases in cytochrome P450 3A activity. [PDF]

Front Pharmacol
Fashe MM, Lee J, Grieco JT, Fallon JK, Mulrenin IR, Gower MN, Jackson KD, Boggess KA, Lee CR.   +8 more
europepmc   +1 more source

Managing Drug-Drug Interactions Involving the Non-Prescription Opioid Loperamide Through Physiologically Based Pharmacokinetic Modeling. [PDF]

CPT Pharmacometrics Syst Pharmacol
Zhou Z, Ainslie GR, Li M, Dinh J, Zamek-Gliszczynski MJ, Zhao P, Paine MF.   +6 more
europepmc   +1 more source

Effect of Rifampicin on the Pharmacokinetics of Valemetostat and Its Primary Metabolite: A Phase 1 Study in Healthy Participants. [PDF]

Clin Transl Sci
Tachibana M, Matsuki S, Kurata A, Fukae M, Shinohara S, Shimizu T.   +5 more
europepmc   +1 more source

Comparative Analysis of Isavuconazole DDIs With Other Azole Antifungal Drugs and PBPK Model-Informed Dosing Recommendations for Anticancer Drugs. [PDF]

CPT Pharmacometrics Syst Pharmacol
Goosen TC, Wu X, Lin J, Cheruvu N, Raber SR, de Figueiredo MLN, Varma MVS.   +6 more
europepmc   +1 more source

1β-Hydroxydeoxycholic acid as an endogenous biomarker in human plasma for assessment of drug-drug interaction with moderate CYP3A inhibitor. [PDF]

Drug Metab Dispos
Chen Y, Huo R, Melo B, Shen JX, Ogasawara K, Xue Y.   +5 more
europepmc   +1 more source

Exploring the roles of cytochrome P450 enzymes and their inhibitors in cancers and non-neoplastic human diseases. [PDF]

Arch Pharm Res
Lee H, Kwon YJ, Chun YJ.
europepmc   +1 more source

Assessing Cytochrome P450 Drug Interaction Risk for Dordaviprone Using Physiologically Based Pharmacokinetic Modeling. [PDF]

CPT Pharmacometrics Syst Pharmacol
Jaiswal S, Patel NK, Jones HM, McFeely S, Faison SL, Tippin T, Naderer O.   +6 more
europepmc   +1 more source